Cognetivity Neurosciences Selected to Present Landmark Research Data at the 34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)

By , in Artificial Intelligence on . Tagged width:

Cognetivity to demonstrate the effectiveness of its ICA platform for the detection of early-stage MS as well as Alzheimer’s and other diseases involving cognitive impairment.

VANCOUVER, Oct. 2, 2018 /CNW/ – Cognetivity Neurosciences Ltd. (the “Company” or “Cognetivity”) (CSE: CGN; FWB:1UB; OTCQB: CGNSF) announced that it has been selected to present landmark results from its ongoing research into the use of the company’s Integrated Cognitive Assessment in the detection of early stage cognitive impairment associated with Multiple Sclerosis at the 34th congress of the European Committee For Treatment and Research In Multiple Sclerosis (MS) (ECTRIMS), held in Berlin, Germany.

The European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) is a non-profit organisation and an independent representative European-wide organisation devoted to Multiple Sclerosis. ECTRIMS works with researchers and clinicians of its member countries and with other organisations that share similar missions and objectives on a worldwide scale, creating networking and collaboration opportunities.

In a talk titled ‘A brief language-independent and self-administered computerized test for cognitive assessment in multiple sclerosis (MS)‘, Cognetivity’s Chief Scientific Officer, Dr. Seyed-Mahdi Khaligh-Razavi will present an overview of the company’s unique AI-based approach, and deliver positive results from ongoing trials into the effectiveness of its proprietary Integrated Cognitive Assessment (ICA) platform for early detection of cognitive impairment in populations of Multiple Sclerosis patients.

The results that will be included in the presentation are as follows:

  • Details on the ICA, a five-minute test delivered via Apple iPads, the results from which are unaffected by culture, language and education, and which can be carried out unsupervised, meaning there is no need for health professionals to administer, a high cost factor with existing tests;
  • Data demonstrating the ICA’s excellent consitency for repeated testing and high level of convergent validity with the highly sensitive and expert-administered BICAMS battery of cognitive tests;
  • Data demonstrating the ICA test’s ability to discriminate between MS patients and healthy control subjects;
  • Data demonstrating the ICA’s high level of accuracy in discriminating cognitively normal from cognitively impaired participants; and
  • Data demonstrating that the ICA test showed no learning bias, making it suitable for frequent monitoring of cognitive performance.

Select attendees of the meeting include leading global pharmaceutical companies Merck, Novartis, Roche and Sanofi and leading academics from the field of MS research from institutions such as Cambridge University, Harvard Medical School, Massachussetts General Hospital, University College London and UCSF.

Cognetivity’s CEO, Dr Sina Habibi said: “We are very excited that our Chief Scientific Officer, Dr. Khaligh-Razavi, is presenting these results at the ECTRiMS meeting, a very prestigious MS conference. What is particularly important is that we are able to demonstrate that our ICA platform can be used in other disease areas over and above our excellent, research-backed capability in Alzheimer’s disease and mild cognitive impairment (MCI). The fact that the ICA is able to detect the early signs of cognitive impairment associated with MS and that it performs very well compared with a highly sensitive, time consuming, expert-administered cognitive test demonstrates its effectiveness in a number of disease areas. The advantages of our platform in terms of sensitivity, usability, administration cost and repeatability over existing testing methods are clear and, based on those factors, we believe our technology has an important role to play in the future of cognitive testing in a growing number of major disease areas.”

Cognitive impairment is increasingly recognized to be a core feature of MS, with important implications for the everyday life of individuals with MS and for disease management. There are an estimated 2.3 million sufferers worldwide and the global therapeutics market for MS estimated to reach US $24.8 billion by 2024. Early detection of cognitive impairment in MS is an important aspect of the clinical appraisal of sufferers, as its presence has a negative influence on physical independence and competence in daily activities and currently, cognitive testing involves time-consuming, expert administered pen and paper tests. There is a widely recognized and urgent need for an easy to administer test with the ability to reliably detect and regularly monitor cognitive ability in MS patients in order to allow clinicians to direct the most effective treatment to sufferers.

About Cognetivity Neurosciences Ltd.

Cognetivity is a technology company developing a cognitive testing platform, the Integrated Cognitive Assessment (ICA) for use in medical and commercial environments. Cognetivity’s ICA uses Artificial Intelligence and machine learning techniques to help detect the earliest signs of impairment by testing the performance of large areas of the brain, potentially allowing early diagnosis of dementia. Cognetivity aims to develop the ICA through planned clinical studies to the market in North America and Europe.

For more information please visit – www.cognetivity.com

ON BEHALF OF THE BOARD

 “Sina Habibi”                                               

Sina Habibi
Chief Executive Officer and Director

FORWARD LOOKING STATEMENTS:

The forward-looking information contained in this press release is made as of the date of this press release and, except as required by applicable law, the Company does not undertake any obligation to update publicly or to revise any of the included forward-looking information, whether as a result of new information, future events or otherwise, except as may be required by law. By its very nature, such forward-looking information requires the Company to make assumptions that may not materialize or that may not be accurate. This forward-looking information is subject to known and unknown risks and uncertainties and other factors, which may cause actual results, levels of activity and achievements to differ materially from those expressed or implied by such information.

The Exchange does not accept responsibility for the adequacy or accuracy of this release

SOURCE Cognetivity Neurosciences Ltd